Print Share

Implantable cardioverter defibrillator improves survival in patients with heart failure

Institution:

School of Medicine and Dentistry at the University of Rochester Medical Center

Researchers:

Arthur J. Moss, M.D., Bradford C. Berk, M.D., Ph.D. Distinguished Professor of Cardiology, University of Rochester School of Medicine and Dentistry

Impact:

Moss led the MADIT (Multicenter Automatic Defibrillator Implantation Trial) series of trials that demonstrated that preventive therapy with an implantable cardioverter defibrillator or ICD – a device that detects potentially fatal arrhythmias and shocks the heart back into a normal rhythm – significantly reduces the risk of death in heart attack survivors. This finding changed medical guidelines nationwide and led to the use of ICDs in millions of patients.

Timeline:

The finding that ICDs reduce death and increase survival was published in the New England Journal of Medicine in 2002.

Topics

AgingBasic ScienceCancerCardiovascularClinical ResearchDiagnosticsDrug DevelopmentFeaturedGeneticsImmune SystemInfectious DiseaseMedical DeviceMental HealthNeurodegenerativeNobel PrizePediatricsPublic HealthRespiratorySurgical AdvancementTechnologyTreatment AdvancesVaccines

Schools

Albany Medical CollegeAlbert Einstein College of MedicineCity University of New York School of MedicineColumbia University College Of Physicians and SurgeonsHofstra Northwell School of Medicine at Hofstra UniversityIcahn School of Medicine at Mount SinaiJacobs School of Medicine and Biomedical Sciences, the University at BuffaloNew York Institute of Technology College of Osteopathic MedicineNew York Medical CollegeNew York University School of MedicineSchool of Medicine and Dentistry at the University of Rochester Medical CenterStony Brook University School of MedicineSUNY Downstate Medical CenterSUNY Upstate Medical UniversityTouro College of Osteopathic MedicineWeill Cornell MedicineWeill Cornell Medicine, NewYork-Presbyterian